Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

Nkarta (NASDAQ:NKTX - Free Report) had its price target cut by Mizuho from $16.00 to $14.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Needham & Company LLC reduced their price objective on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, May 15th. Stifel Nicolaus dropped their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Finally, William Blair reiterated a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Nkarta presently has an average rating of "Buy" and a consensus target price of $14.33.

Nkarta Trading Down 2.6%

NKTX stock traded down $0.05 during trading on Tuesday, hitting $1.86. The company had a trading volume of 458,497 shares, compared to its average volume of 1,062,269. The firm has a market capitalization of $131.98 million, a price-to-earnings ratio of -0.99 and a beta of 0.72. The business has a 50 day moving average of $1.85 and a 200 day moving average of $2.06. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.01. As a group, equities analysts predict that Nkarta will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Nkarta

Several hedge funds and other institutional investors have recently bought and sold shares of NKTX. Sequoia Financial Advisors LLC bought a new stake in Nkarta in the fourth quarter worth about $31,000. Thrivent Financial for Lutherans acquired a new stake in Nkarta during the 4th quarter worth about $258,000. American Century Companies Inc. raised its holdings in Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock worth $226,000 after buying an additional 7,378 shares during the period. Sei Investments Co. acquired a new stake in Nkarta during the 4th quarter worth about $57,000. Finally, Samalin Investment Counsel LLC acquired a new stake in Nkarta during the 4th quarter worth about $211,000. 80.54% of the stock is currently owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.